Home MonitoringCATCHNCT04498728
Cardiac Acute Transitioning Care to Home (CATCH) App Data Repository
An observational study of Home Monitoring and Congenital Heart Disease, run by Children's Mercy Hospital Kansas City at 1 site in United States.
Trial summary
This repository will consist of clinically derived data and images of patients with congenital heart disease from the time of birth until they have reached one of the following outcomes: transition to outpatient care that has not resulted in readmission in 30 days after hospital discharge, death, weaned off… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Home Monitoring, Congenital Heart Disease, Mobile Health
- What is being tested?
- Mobile Health Application for Remote Monitoring
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Jul 2020to 15 Nov 2021
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Children after hospitalization for heart surgery that required ICU care
Who may be able to join
- • Subjects with congenital heart disease that have been hospitalized for more than 30 days,
- Subjects being discharged with readmissions more than twice to critical care areas,
- Subject with single ventricle physiology that has not been discharged home during the single ventricle interstage period,
- Subjects that are less than 18 years of age,
- Subjects with gastrostomy or nasogastric tubes and congenital heart disease,
- Subjects with congenital heart disease who are at a high risk for transition to the home setting and are not currently enrolled in the CHAMP single ventricle inclusion criteria, and/or
- Subjects at high risk for events as identified by the Directors of the CATCH app Repository.
Who cannot join
- All patients not meeting at least one of the above specified criteria.
Trial locations and contacts
1 site in 1 country.
United States1 site
Children's Mercy Kansas City
Kansas City, Missouri, 64108
About this study
Official title: The Cardiac Acute Transitioning Care to Home (CATCH) Data Repository (CATCH App Repository)
This repository will consist of clinically derived data and images of patients with congenital heart disease from the time of birth until they have reached one of the following outcomes: transition to outpatient care that has not resulted in readmission in 30 days after hospital discharge, death, weaned off supplementary feeding tubes, or clinic visits demonstrating clinical stability with their primary cardiologist, or full bi-ventricular cardiac surgery palliation with improvement in hemodynamic stability. This information will be collected for clinical evaluation and diagnostic purposes and will continue to be stored for potential future research application.
Read the detailed description
Approximately 40,000 infants are born each year with congenital heart disease (CHD), a leading cause of morbidity and mortality in infancy. Progress in surgical, transcatheter, and medical management of newborn CHD has significantly reduced mortality. The CHAMP app (separate IRB # 15030113) has helped to transition high-risk infants with single ventricle congenital heart disease out of the hospital and to second stage cardiac surgery at Children's Mercy Hospital and across the United States with improved survival. Remote monitoring technology and telemedicine is a critical tool to aid clinical care for high risk children with congenital heart disease but has been limited to the single ventricle population in most cases. The benefits of this tool as a standard of care for other children transitioning home may include decreased readmissions, improved weight gain, and remote monitoring for reduced throughput in the emergency room, hospital, and clinic settings. To improve outcomes beyond mortality and into morbidity with other high-risk patients with congenital heart disease, future studies must assess morbidities and quality of outcomes with the application of remote home monitoring with applications like the CHAMP app.
Patients that are discharging from the hospital after complex congenital heart disease surgery and cardiac catheterization are at high risk of events. Adverse outcomes in the year after discharge are of similar magnitude to mortality in hospital and are not only with infants with single ventricle heart disease but may include infants and children that were hospitalized more than 30 days, readmitted to intensive care unit more than once, smaller size for age, younger age at surgery, shunt dependent for pulmonary blood flow, congenital heart disease with complexities such as neurological conditions and supplemental enteral feedings gastrostomy. Over a 6-year period, 6.7% (514/7976) children experienced adverse events including mortality in a report from England after initial discharge from cardiac surgery. In a review of our similar patients from Children's Mercy we have noted a 5.8% mortality in this population.
There is additional focus on expanding transition care in the pediatric cardiac population beyond 30 days after discharge as traditionally followed by the Society of Thoracic Surgeons as a marker of well-state (traditionally 8.3%) and onto 90 days (21% of additional readmissions) to 1 year after discharge. Children had unplanned hospital readmissions during the first year after cardiac surgery that were between 31 and 90 days after discharge that could have possibly been prevented with the aid of remote technology in additional to ambulatory care by a specialized advanced practice nurse. Higher rates of readmissions were seen with those in lower socioeconomic areas (through zip codes), living closer to the hospital (potentially a marker of access to care and rurality), higher STAT category, longer intubation, and longer ICU length of stay were all markers for higher risk of later readmission after 31 days of discharge.
Combining the advancements with CHAMP app with the expert care teams with advanced practice nurses, a new standard of care for an expanded group of high-risk infants and children transitioning home after cardiac surgery and in-hospital care can be established. The research and ability to improve the understanding of how this process can be applied to an expanded population that has been identified as high risk is key for implementation and sustainability of a high risk transition care program.
- Conditions
- Home Monitoring, Congenital Heart Disease, Mobile Health
- Being tested
- Mobile Health Application for Remote Monitoring
- Keywords
- congenital heart disease
- Medical subject headings
- Heart Defects, Congenital
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mobile Health Application for Remote MonitoringOther
Also called CHAMP
The use of the CATCH application (CATCH App), and any data and images obtained from the use of the CATCH App, will all be performed as standard of care for patients at Children's Mercy Kansas City, and will be for the clinical treatment of patients. Data will be collected for the repository for all patients submitting data through the use of the CATCH App. Clinical care team will follow the patients after discharge home from the hospital.
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of children that had 30 day survival after hospital discharge
Survival of child after hospital discharge
Measured: 1 month
Number of children that had Readmission after initiation hospital discharge
Hospital readmission after initial discharge
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2020
- Study start29 Jul 2020
- Primary completion29 May 2021
- Study completion15 Nov 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Home MonitoringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 6 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lori Erickson, PhD, Principal investigator, Children's Mercy Hospital Kansas City
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04498728
- Sponsor's protocol ID
- Study00001436
- Acronym
- CATCH
- Status last verified
- Nov 2021
- First submitted
- 30 Jul 2020
- Last updated
- 18 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Shirali G, Erickson L, Apperson J, Goggin K, Williams D, Reid K, Bradley-Ewing A, Tucker D, Bingler M, Spertus J, Rabbitt L, Stroup R. Harnessing Teams and Technology to Improve Outcomes in Infants With Single Ventricle. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):303-11. doi: 10.1161/CIRCOUTCOMES.115.002452. Epub 2016 May 10.
PubMed 27166202Lushaj EB, Hermsen J, Leverson G, MacLellan-Tobert SG, Nelson K, Amond K, Anagnostopoulos PV. Beyond 30 Days: Analysis of Unplanned Readmissions During the First Year Following Congenital Heart Surgery. World J Pediatr Congenit Heart Surg. 2020 Mar;11(2):177-182. doi: 10.1177/2150135119895212.
PubMed 32093562Bingler M, Erickson LA, Reid KJ, Lee B, O'Brien J, Apperson J, Goggin K, Shirali G. Interstage Outcomes in Infants With Single Ventricle Heart Disease Comparing Home Monitoring Technology to Three-Ring Binder Documentation: A Randomized Crossover Study. World J Pediatr Congenit Heart Surg. 2018 May;9(3):305-314. doi: 10.1177/2150135118762401.
PubMed 29692236
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Cardiac Acute Transitioning Care to Home (CATCH) Data Repository (CATCH App Repository)
- ClinicalTrials.gov ID
- NCT04498728
- Acronym / sponsor ID
- CATCH / Study00001436
- Conditions
- Home Monitoring, Congenital Heart Disease, Mobile Health
- Keywords
- congenital heart disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Children's Mercy Hospital Kansas CityUniversity, hospital or other
- Study start
- 29 Jul 2020 (actual)
- Primary completion
- 29 May 2021 (actual)
- Study completion
- 15 Nov 2021 (actual)
- First posted
- 4 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This repository will consist of clinically derived data and images of patients with congenital heart disease from the time of birth until they have reached one of the following outcomes: transition to outpatient care that has not resulted in readmission in 30 days after hospital discharge, death, weaned off supplementary feeding tubes, or clinic visits demonstrating clinical stability with their primary cardiologist, or full bi-ventricular cardiac surgery palliation with improvement in hemodynamic stability. This information will be collected for clinical evaluation and diagnostic purposes and will continue to be stored for potential future research application.
Detailed description
Approximately 40,000 infants are born each year with congenital heart disease (CHD), a leading cause of morbidity and mortality in infancy. Progress in surgical, transcatheter, and medical management of newborn CHD has significantly reduced mortality. The CHAMP app (separate IRB # 15030113) has helped to transition high-risk infants with single ventricle congenital heart disease out of the hospital and to second stage cardiac surgery at Children's Mercy Hospital and across the United States with improved survival. Remote monitoring technology and telemedicine is a critical tool to aid clinical care for high risk children with congenital heart disease but has been limited to the single ventricle population in most cases. The benefits of this tool as a standard of care for other children transitioning home may include decreased readmissions, improved weight gain, and remote monitoring for reduced throughput in the emergency room, hospital, and clinic settings. To improve outcomes beyond mortality and into morbidity with other high-risk patients with congenital heart disease, future studies must assess morbidities and quality of outcomes with the application of remote home monitoring with applications like the CHAMP app.
Patients that are discharging from the hospital after complex congenital heart disease surgery and cardiac catheterization are at high risk of events. Adverse outcomes in the year after discharge are of similar magnitude to mortality in hospital and are not only with infants with single ventricle heart disease but may include infants and children that were hospitalized more than 30 days, readmitted to intensive care unit more than once, smaller size for age, younger age at surgery, shunt dependent for pulmonary blood flow, congenital heart disease with complexities such as neurological conditions and supplemental enteral feedings gastrostomy. Over a 6-year period, 6.7% (514/7976) children experienced adverse events including mortality in a report from England after initial discharge from cardiac surgery. In a review of our similar patients from Children's Mercy we have noted a 5.8% mortality in this population.
There is additional focus on expanding transition care in the pediatric cardiac population beyond 30 days after discharge as traditionally followed by the Society of Thoracic Surgeons as a marker of well-state (traditionally 8.3%) and onto 90 days (21% of additional readmissions) to 1 year after discharge. Children had unplanned hospital readmissions during the first year after cardiac surgery that were between 31 and 90 days after discharge that could have possibly been prevented with the aid of remote technology in additional to ambulatory care by a specialized advanced practice nurse. Higher rates of readmissions were seen with those in lower socioeconomic areas (through zip codes), living closer to the hospital (potentially a marker of access to care and rurality), higher STAT category, longer intubation, and longer ICU length of stay were all markers for higher risk of later readmission after 31 days of discharge.
Combining the advancements with CHAMP app with the expert care teams with advanced practice nurses, a new standard of care for an expanded group of high-risk infants and children transitioning home after cardiac surgery and in-hospital care can be established. The research and ability to improve the understanding of how this process can be applied to an expanded population that has been identified as high risk is key for implementation and sustainability of a high risk transition care program.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Children after hospitalization for heart surgery that required ICU care
Key inclusion criteria (7 listed)
- • Subjects with congenital heart disease that have been hospitalized for more than 30 days,
Key exclusion criteria (1 listed)
- All patients not meeting at least one of the above specified criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mobile Health Application for Remote MonitoringAlso: CHAMPThe use of the CATCH application (CATCH App), and any data and images obtained from the use of the CATCH App, will all be performed as standard of care for patients at Children's Mercy Kansas City, and will be for the clinical treatment of patients. Data will be collected for the repository for all patients submitting data through the use of the CATCH App. Clinical care team will follow the patients after discharge home from the hospital. | Other | – |
Primary outcome
Number of children that had 30 day survival after hospital discharge
Time frame: 1 month
Survival of child after hospital discharge
Number of children that had Readmission after initiation hospital discharge
Time frame: 2 months
Hospital readmission after initial discharge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2021.
- Results publication: PubMed 27166202Shirali G, Erickson L, Apperson J, Goggin K, Williams D, Reid K, Bradley-Ewing A, Tucker D, Bingler M, Spertus J, Rabbitt L, Stroup R. Harnessing Teams and Technology to Improve Outcomes in Infants With Single Ventricle. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):303-11. doi: 10.1161/CIRCOUTCOMES.115.002452. Epub 2016 May 10.
- Results publication: PubMed 32093562Lushaj EB, Hermsen J, Leverson G, MacLellan-Tobert SG, Nelson K, Amond K, Anagnostopoulos PV. Beyond 30 Days: Analysis of Unplanned Readmissions During the First Year Following Congenital Heart Surgery. World J Pediatr Congenit Heart Surg. 2020 Mar;11(2):177-182. doi: 10.1177/2150135119895212.
- Results publication: PubMed 29692236Bingler M, Erickson LA, Reid KJ, Lee B, O'Brien J, Apperson J, Goggin K, Shirali G. Interstage Outcomes in Infants With Single Ventricle Heart Disease Comparing Home Monitoring Technology to Three-Ring Binder Documentation: A Randomized Crossover Study. World J Pediatr Congenit Heart Surg. 2018 May;9(3):305-314. doi: 10.1177/2150135118762401.
- Individual participant dataSharing planned: No
Related trials for Home Monitoring
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
Active, not recruiting
Parent Tube Weaning Interviews
Feeding Difficulties, Remote Patient Monitoring
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lori Erickson, PhD principal investigator
Children's Mercy Hospital Kansas City
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Home Monitoring and Congenital Heart Disease, run by Children's Mercy Hospital Kansas City at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of children that had 30 day survival after hospital discharge (time frame: 1 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04498728, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2021.